PMID- 34844413
OWN - NLM
STAT- MEDLINE
DCOM- 20220330
LR  - 20220531
IS  - 1699-5198 (Electronic)
IS  - 0212-1611 (Linking)
VI  - 39
IP  - 2
DP  - 2022 Mar 29
TI  - Will intestinal flora therapy become a new target in type-2 diabetes mellitus? A 
      review based on 13 clinical trials.
PG  - 425-433
LID - 10.20960/nh.03866 [doi]
AB  - Background: diabetes mellitus (DM) is a chronic disease and its pathogenesis is 
      still inconclusive. Current evidence suggests an association between intestinal 
      flora and type-2 diabetes mellitus (T2DM). In this paper, we summarized the 
      current research, determining whether intestinal flora may become a new method to 
      treat T2DM, and providing a theoretical basis and literature references for the 
      prevention of T2DM based on the regulation of intestinal flora. Method: we 
      carried out a review based on 13 published clinical trials to determine the 
      correlation between T2DM and intestinal flora, and between changes in clinical 
      outcomes and in intestinal flora in the development of T2DM; to assess the 
      pathological mechanisms; and to discuss the treatment of diabetes based on 
      intestinal flora. Results: we found that intestinal flora is involved in the 
      occurrence and development of T2DM. Several pathological mechanisms may be 
      involved in the process, including improving the gut barrier, alleviating 
      inflammation, increasing glucagon-like peptide (GLP) 1 and GLP 2, increasing the 
      production of short-chain fatty acids (SCFAs), and so on. Several measures based 
      on intestinal flora, including exercise, food, specific diets, drugs and 
      probiotics, would be used to treat and even prevent T2DM. Conclusions: 
      high-quality studies are required to better understand the clinical effects of 
      intestinal flora in T2DM.
FAU - Wang, Fujie
AU  - Wang F
AD  - Nutritional Department. The First Affiliated Hospital of Nanjing Medical 
      University.
FAU - Zhao, Ting
AU  - Zhao T
AD  - Nutritional Department. The First Affiliated Hospital of Nanjing Medical 
      University.
FAU - Wang, Weiwei
AU  - Wang W
AD  - Nutritional Department. The First Affiliated Hospital of Nanjing Medical 
      University.
FAU - Dai, Qianqian
AU  - Dai Q
AD  - Nutritional Department. Xuzhou Cancer Hospital.
FAU - Ma, Xianghua
AU  - Ma X
AD  - Nutritional Department. The First Affiliated Hospital of Nanjing Medical 
      University.
LA  - eng
PT  - Journal Article
PT  - Review
TT  -  inverted question markPuede la terapia de flora intestinal convertirse en un nuevo objetivo para la 
      diabetes mellitus de tipo 2? Revision basada en 13 ensayos clinicos.
PL  - Spain
TA  - Nutr Hosp
JT  - Nutricion hospitalaria
JID - 9100365
RN  - 0 (Fatty Acids, Volatile)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Clinical Trials as Topic
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Fatty Acids, Volatile/therapeutic use
MH  - *Gastrointestinal Microbiome
MH  - Glucagon-Like Peptide 1/pharmacology/therapeutic use
MH  - Humans
MH  - *Probiotics/therapeutic use
OTO - NOTNLM
OT  - Flora intestinal. Diabetes mellitus de tipo 2. Tratamiento.
EDAT- 2021/12/01 06:00
MHDA- 2022/03/31 06:00
CRDT- 2021/11/30 05:30
PHST- 2021/12/01 06:00 [pubmed]
PHST- 2022/03/31 06:00 [medline]
PHST- 2021/11/30 05:30 [entrez]
AID - 10.20960/nh.03866 [doi]
PST - ppublish
SO  - Nutr Hosp. 2022 Mar 29;39(2):425-433. doi: 10.20960/nh.03866.